The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of surgical complications in patients with metastatic clear cell renal cell carcinoma (mccRCC) receiving perioperative cabozantinib and nivolumab on Cyto-KIK clinical trial.
 
Karie Runcie
No Relationships to Disclose
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Biren Saraiya
Honoraria - Eisai
Research Funding - Merck (Inst); Regeneron (Inst)
 
Venkatesh Krishnamurthi
No Relationships to Disclose
 
Byron H Lee
No Relationships to Disclose
 
Christopher B. Anderson
No Relationships to Disclose
 
Guarionex Joel DeCastro
No Relationships to Disclose
 
James M. McKiernan
No Relationships to Disclose
 
Matthew Dallos
No Relationships to Disclose
 
Tina M. Mayer
Honoraria - EMD Serono; Exelixis
Consulting or Advisory Role - AstraZeneca; Beacon Bioscience/ICON Medical; Novartis
Research Funding - Merck (Inst); Pfizer/EMD Serono; Sotio (Inst)
 
Melanie Marron
No Relationships to Disclose
 
Alexandria Kulik
No Relationships to Disclose
 
Eric A. Singer
Consulting or Advisory Role - Aura Biosciences; Johnson & Johnson/Janssen; Merck; Vyriad
Research Funding - Astellas Medivation
 
Mark N. Stein
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Vaccitech; Xencor
Research Funding - Advaxis (Inst); Bellicum Pharmaceuticals; Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)